Sales at risk of pharmaceuticals due to patent expiries U.S. 2022
In 2028, around 15.3 billion U.S. dollars of Keytruda sales are expected to be at risk due to the drug patent expiring. This statistic illustrates the sales at risk of pharmaceutical products in the U.S. due to approaching drug patent expiries, as of 2022.